Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents

Clin Infect Dis. 2021 Dec 6;73(11):2145-2147. doi: 10.1093/cid/ciab300.

Authors

Jens T Van Praet^{1

2}, Stefaan Vandecasteele¹, Anneleen De Roo³, An S De Vriese^{1

2}, Marijke Reynders⁴

Affiliations

¹ Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium.
² Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
³ Curando, Ruiselede, Belgium.
⁴ Department of Laboratory Medicine, Medical Microbiology, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium.

No abstract available

Publication types

Letter
Comment

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines*
COVID-19*
Humans
Nursing Homes
RNA, Messenger
SARS-CoV-2

Substances

COVID-19 Vaccines
RNA, Messenger
BNT162 Vaccine